Neoadjuvant immunotherapy for melanoma is now ready for clinical practice

Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Nature Medicine 2023-06, Vol.29 (6), p.1310-1312
Hauptverfasser:	Garbe, Claus, Dummer, Reinhard, Amaral, Teresa, Amaria, Rodabe N., Ascierto, Paolo A., Burton, Elizabeth M., Dreno, Brigitte, Eggermont, Alexander M. M., Hauschild, Axel, Hoeller, Christoph, Kaufmann, Roland, Lebbe, Celeste, Mandala, Mario, Menzies, Alexander M., Moreno, David, Michielin, Olivier, Nathan, Paul, Patel, Sapna P., Robert, Caroline, Schadendorf, Dirk, Lorigan, Paul C., Scolyer, Richard A., Tawbi, Hussein A., van de Wiel, Bart A., Blank, Christian, Long, Georgina V.
Format:	Artikel
Sprache:	eng
Schlagworte:	692/308 692/699/67/1059/2325 Biomedical and Life Sciences Biomedicine Breast cancer Cancer Research Cancer therapies Chemotherapy Clinical medicine Comment Drug dosages Immunotherapy Infectious Diseases Life Sciences Melanoma Metabolic Diseases Molecular Medicine Neurosciences Regulatory approval Surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Individuals with cutaneous melanoma who are treated with neoadjuvant immunotherapy show a substantial improvement; this should be incorporated into standard care.
ISSN:	1078-8956 1546-170X 1744-7933
DOI:	10.1038/s41591-023-02336-1